WuXi unveils WuXia ADCC PLUS platform to develop afucosylated antibodies
Derived from the company’s WuXia cell line platform, WuXia ADCC PLUS is a superior-performing and high-yielding mammalian cell…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
25 Jan 24
Derived from the company’s WuXia cell line platform, WuXia ADCC PLUS is a superior-performing and high-yielding mammalian cell…
25 Jan 24
Under this new partnership, VGXI will serve as a trusted plasmid DNA manufacturer to support Resilience's advanced therapy…
24 Jan 24
Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics
23 Jan 24
Inhalation Sciences AB has entered a new partnership with Actarmo Medical GmbH, a respiratory drug development services provider…
17 Jan 24
The WuXiBody platform enables almost any mAb sequence pairs to be assembled into bispecific constructs that are expected…
16 Jan 24
Armatus Bio’s lead candidate for CMT1A has received orphan drug designation and rare paediatric drug designation from the…
12 Jan 24
Under the partnership, ElevateBio BaseCamp scientists will gain access to Xcellbio’s Avatar incubator system for cell therapy research…
12 Jan 24
The partnership is intended to develop a suite of AI models to generate synthetically accessible biologically active compounds…
12 Jan 24
Illumina Ventures Labs is well positioned to enable early-stage companies to accelerate the time needed to reach their…
12 Jan 24
Approach leverages novel mechanisms such as remyelination and anti-neuroinflammation to address a broad spectrum of degenerative CNS diseases